Aim Chronic immunosuppressant use increases the risk of septic complications after colectomy; however, adverse effects on other organ systems remain poorly understood. The aim of this study was to evaluate the multisystem organ effect(s) of chronic immunosuppressant(s) in colorectal cancer patients.
Introduction
Chronic immunosuppressant(s) are widely utilized for treatment of autoimmune diseases, inflammatory bowel disease, endocrine disorders, pulmonary conditions and a host of other chronic disease processes. Corticosteroids, a subset of immunosuppressant medications, remain one of the most commonly prescribed medications in the USA, despite a well-documented profile of adverse effects [1] . In the surgical population, chronic steroid use is associated with increased rates and severity of wound complications, anastomotic leak and intra-abdominal infection in the postoperative period [2] . These complications are largely attributed to the inhibition of wound healing [3] . Enteric contamination at the time of surgery may further compound patient risk for septic complications and contribute to overall morbidity and mortality [4] [5] [6] [7] [8] . To reduce morbidity and mortality, surgical management of high-risk patients may sometimes involve end colostomy or prophylactic diverting ileostomy to minimize the severity of infective complications. The data are less clear on surgical complications related to other classes of chronic immunosuppressants such as infliximab and biologic therapies utilized for the treatment of autoimmune and inflammatory bowel disorders. While surgeons may expect a higher risk of wound or anastomotic complications due to chronic immunosuppressant use, minimal evidence exists regarding organ-specific outcomes on colorectal cancer patients undergoing surgical intervention.
Colorectal cancer is the third leading cause of cancer deaths in women and the second in men, affecting over 145 000 new patients each year [9] . Most new diagnoses are in patients over the age of 50 years [9] . Advanced age is associated with increased risk of colorectal malignancies, as well as numerous comorbid conditions such as asthma and rheumatoid arthritis that are medically managed with immunosuppressant(s). With the presence of comorbidity amongst colorectal cancer patients over 40%, recent projections that half of all operations are performed on individuals aged 65 and older, and estimates of overall surgical volume increasing 14%-47% by 2020, understanding the effect of immunosuppressant use on patient outcomes is of great importance to surgeons [10] [11] [12] .
While the risk of septic complications following surgery in chronic immunosuppressant patients has been well studied, there remains a poor understanding of how chronic immunosuppressant(s) systemically affect diseased organ systems in the postoperative setting. While chronic immunosuppressant use has been linked in animal models to increased risk of myocardial infarctions and similar atherogenic cardiovascular events [13] , the association between systemic immunosuppressive medications on pulmonary, neurological, cardiovascular and renal complications is not well understood in the colorectal cancer population. Here, our aim was to study the multisystem organ effect of chronic immunosuppressant use in colorectal cancer patients undergoing surgical intervention using a clinically validated dataset. We hypothesized that both septic and organ-system complications were worsened in this population. Given the obvious bias of higher comorbidities in patients taking chronic immunosuppressant(s), we hypothesized that, following propensity score matching for comorbidities and other contributory factors, chronic immunosuppressant use would still be associated with worsened 30-day overall morbidity and mortality.
Method Data collection
The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) is a surgery-specific database which samples and records operations across the USA from participating institutions. It is among the first national, validated means for evaluating risk-adjusted surgical outcomes and improving the quality of surgical care. Clinical data including patient demographics, preoperative risk factors, and perioperative and postoperative outcomes within 30 days of the index surgery are collected. Currently, over 600 hospitals participate in NSQIP data collection with over 250 variables available for charting. The ACS-NSQIP administration periodically audits the data to ensure high reliability. Baseline demographics included age, BMI, male gender, presence of comorbid disease, diabetes, work relative value units (work RVUs), presence of preoperative sepsis, emergency case, wound classification and operative time. Work RVUs were used to control for case complexity and improve the general application of findings [14] . Procedure types were not limited by current procedural terminology; however, evaluation of the cases demonstrated that more than 98% of included cases involved bowel resection. Comorbidities within the ACS-NSQIP were grouped by organ system into five categories as previously reported [15, 16] . Specifically, the groupings comprised vascular (revascularization for peripheral vascular disease, claudication, rest pain, amputation or gangrene), cardiac (heart failure, hypertension, coronary artery disease including angina, myocardial infarction within 6 months of index operation, percutaneous cardiac intervention or cardiac operation), pulmonary (dyspnoea, chronic obstructive pulmonary disease, current pneumonia, ventilator dependence), neurological (stroke with or without neurological deficit, transient ischaemic attacks, hemiplegia, paraplegia, quadriplegia or impaired sensorium) and renal (renal disease, end-stage renal disease). Primary outcomes included 30-day mortality and 30-day overall morbidity. Overall morbidity consisted of all minor [surgical site infection (SSI), pneumonia, deep venous thrombosis or thrombophlebitis, unplanned reintubation, urinary tract infection, peripheral nerve injury] and serious morbidities (organ space infection, sepsis, septic shock, wound disruption, pulmonary embolism, ventilator dependence greater than 48 h after surgery, progressive renal insufficiency, acute renal failure, stroke, coma, cardiac arrest requiring cardiopulmonary resuscitation, myocardial infarction, blood transfusion for bleeding). Additional outcomes included total hospital length of stay, postoperative length of hospital stay, mortality, serious morbidity, minor morbidity, system-specific complications, septic complications, SSI and reoperation.
Statistical analysis
Univariate analyses of demographics, work RVUs and operative time were performed using chi-squared for nominal and ordinal variables and the independent samples t test or Mann-Whitney U test for continuous variables. Following this, analyses were adjusted using propensity score matching algorithms. Specifically, 1:1 near neighbour matching with both discard and a caliper of 0.2 was utilized in conjunction with GAMLogit smoothing of all continuous variables. A literature review associated with 30-day morbidity and mortality in colorectal cancer patients demonstrated a multitude of variables, which were carefully evaluated for relevance to our study question. Some variables were excluded because our time period did not include colectomy-targeted variables. Ultimately, variables included for propensity matching were age, BMI, work RVUs, vascular comorbidities, cardiac comorbidities, pulmonary comorbidities, renal comorbidities and diabetes. Data analysis was performed using SPSS FOR WINDOWS version 22 (IBM, Somers, New York, USA) and R package 2.15.2 (R Core Team, Vienna, Austria). Univariate analysis was again performed using chi-squared for nominal and ordinal variables with frequencies reported. An independent samples t test or Mann-Whitney U test was used for continuous variables with median and interquartile range or mean and standard deviation reported, as indicated. Odds ratios with 95% confidence intervals were calculated for outcome variables. Any P value < 0.05 was considered statistically significant. Approval for this study was obtained through an agreement with ACS-NSQIP and exempt status from the East Carolina University Institutional Review Board.
Results

Patient and operative characteristics
A total of 50 766 patients were queried during the study period with 1203 (2.4%) identified via the STER-OID variable. After propensity matching, 1197 patients in each cohort were investigated with no differences seen in age, BMI, male gender, work RVUs and preoperative sepsis (Table 1 ). Additionally, rates of vascular, cardiac, pulmonary, neurological, renal and diabetic comorbidity were similar between propensity-matched groups. Similar rates of laparoscopic approach, operative times and rates of emergent surgery were observed between the groups (Table 2 ). No differences in wound classification (i.e. clean, clean-contaminated etc.) were identified between groups, with most cases in both cohorts marked as clean-contaminated.
Postoperative outcomes
Chronic immunosuppressant patients demonstrated longer total hospital stay (11.4 AE 11.7 vs 9.5 AE 9.4 days, P < 0.001) and postoperative length of stay (9.4 AE 9.2 vs 8.1 AE 7.6 days, P < 0.001) ( Table 3 ).
The 30-day mortality (5.7% vs 3.4%, P = 0.008) was significantly higher in patients taking chronic immunosuppressant(s). Additionally, the 30-day overall (35.4% vs 29.0%, P = 0.001), serious (24.4% vs 18.4%, P < 0.001) and minor morbidities (23.3% vs 19.4%, P = 0.02) were higher in the chronic immunosuppressant cohort. No differences were seen in cardiovascular, pulmonary, renal or neurological complications between the two groups. Septic complications (10.6% vs 7.9%, P = 0.02) and SSIs (15.3% vs 12.3%, P = 0.03) were significantly elevated in patients on chronic immunosuppressant(s). Rates of reoperation were similar between the groups.
Discussion
Here, we demonstrate that, following propensity matching for patient demographics and comorbidities, use of chronic immunosuppressant(s) in colorectal cancer patients undergoing surgical intervention is associated with worsened 30-day mortality, overall morbidity, serious morbidity and minor morbidity. Contrary to our hypothesis, the source of worsened mortality and morbidity appears to be related to higher rates of sepsis and surgical site infective complications, not organ-system complications related to chronic conditions for which patients might be taking immunosuppressants. This suggests that postoperative cardiovascular events, worsening pulmonary function, renal insufficiency and other organ-specific complications occurring in the postoperative period may be associated with alternative stressors including fluid shifts, hypercoagulable states and general anaesthetic physiological effects, similar to what occurs in patients not taking chronic immunosuppressants. Further, our study suggests a need for careful preoperative discussion of infective complication risks, more aggressive postoperative evaluation and management of infective complications, and a need for future studies to determine pathways for infective risk reduction in those taking chronic immunosuppressants.
As corticosteroids affect all aspects of the healing process through decreased macrophage infiltration into the wound [17] , attenuating fibroblast proliferation and wound re-epithelialization [18, 19] , and decreased tensile strength of wounds through reduced collagen deposition and impaired turnover [3, [20] [21] [22] , their detrimental effect on surgical wounds is expected. Specifically, SSIs and anastomotic leak are associated with the use of chronic steroids [2, 3, 23, 24] and our results support prior studies implicating chronic steroid use in worsened mortality and morbidity [8, 25, 26] . While studies are limited in comparing short-and longterm use of steroids before surgery, Furst et al. investigated animal model anastomotic burst pressures with no difference observed at 4 days of steroid use, while a significant difference was shown when steroids were given for longer periods of time [23] . Patients undergoing surgery for colorectal malignancy may benefit from septic and SSI risk minimization via preoperative medical optimization and augmented wound closure strategies that include delayed primary closure and negative pressure dressings. Although not specifically answerable in this study due to lack of granularity regarding anastomotic leak, consideration of stoma (i.e. end or diverting) creation in these high-risk patients may be reasonable. Further study is required to answer that question. While our study could only evaluate 30-day outcomes, long-term outcomes in colorectal cancer patients should remain of utmost concern. Khoury et al. have shown that chronic immunosuppression alone was associated with lower 3-year (49.1% vs 76.3%, P = 0.003) and 5-year (45.1% vs 66.2%, P = 0.003) overall survival in patients undergoing surgery for colorectal cancer [27] . Additionally, studies demonstrate worsened overall survival and long-term outcomes in malignancy when complications occur, especially if adjuvant therapy is delayed [28] [29] [30] . With rates of wound complications 2-5 times higher in human studies evaluating direct effects of chronic corticosteroid use [31] , higher risk of leak noted by Khoury et al. [27] , and our current findings, surgeons should carefully counsel their patients regarding risks of surgical intervention for colorectal cancer in the setting of chronic immunosuppressant use. Attention should be paid to discussing the risks of sepsis and SSIs as these appear most associated with chronic immunosuppressant use in this study. While focus should also be on effective management of the patient's underlying chronic comorbidities, immunosuppressant use did not significantly increase rates of system-based complications in this study of colorectal cancer patients.
Despite controlling for demographic factors, operative time and surgical case complexity, overall hospital and postoperative lengths of stay were significantly increased in patients taking chronic immunosuppressant (s). The most reasonable explanation for this finding is increased morbidity through septic and SSI complications, which subsequently require more therapeutic interventions and delay discharge. This is consistent with other publications in the literature [32, 33] . In fact, a significant body of literature reflects the increased risk of both sepsis and septic complications in the population studied here [34] . Because delay in diagnosis of infective and septic complications contributes to increased mortality, early recognition is important in cancer patients with chronic immunosuppressant use. Hypotension prior to initiation of antibiotics and delay in antibiotic initiation may contribute to worsened outcomes and higher mortality, suggesting surgeons be highly vigilant in evaluating and treating their postoperative cancer patients showing signs of infective complication or sepsis [35, 36] . The recent literature suggests no difference between protocol-based care and standard care, but only when delays are minimized in starting therapy [37] . As yet there is no agreed-upon screening tool for sepsis, but adjuncts such as systemic inflammatory response calculators and serum biomarkers such as lactate, C-reactive protein, lactate and procalcitonin are much studied. Ongoing trials may help answer this question for a complicated patient population. Providers are encouraged to give special attention to postoperative colorectal cancer patients on chronic immunosuppressant(s) for signs of infective complications as these patients may be at increased risk for severe morbidity and mortality. Due to study design, our retrospective review of prospectively collected data in the ACS-NSQIP Participant Use File is limited by the possibility of confounding, selection, information and misclassification bias. Appropriate corrections were made during statistical analysis to reduce the effects of these biases but cannot account for all biases. Other limitations include heterogeneous patient factors including procedures performed, differences in hospitals, surgical expertise and lack of randomization. The lack of longer term outcomes is a significant limitation of this study, precluding our ability to link postoperative complications with long-term outcomes. Further, 30-day surgical outcomes are influenced by factors not accounted for in this study including medical staff, resident involvement outside the operating room, patient compliance and many others not included in the NSQIP dataset. Lastly, there exists a significant limitation in data granularity in the STEROID variable utilized. We were unable to subset what immunosuppressants were taken, for how long, at what dose, and other clinically pertinent information. Because data are unclear regarding the role of some immunosuppressant(s) (such as infliximab and other biologics) on postoperative outcomes, inclusion of these patients in the analysis may unduly bias the results demonstrated here. As the STEROID variable defines 'chronic' use as longer than 10 days, we are unable to determine the effect of immunosuppressant use on outcomes based on how long a patient was taking immunosuppressant medications. We are also unable to determine if some patients were taking multiple immunosuppressants, nor assess how combination therapy may or may not place these patients at increased risk for operative complications. Further, it is not possible in this study to elucidate the underlying physiological process responsible for worsened outcomes in colorectal cancer patients on chronic immunosuppressant(s), instead having to infer from prior studies on pathophysiology to suggest a mechanism for the results. These limitations should be considered when reviewing our data. Despite these limitations, the data analysed are considered the most complete multi-institutional clinical data available, with the added advantage of impartial clinical reviewers to help reduce error and bias.
Conclusion
As the numbers of chronic conditions involving treatment with immunosuppressant(s) increase, surgeons must understand patient risk profiles to provide adequate preoperative counselling. In this study, we show that immunosuppressant use is associated with worsened sepsis and infective complications without contributing to organ-specific complications following surgery for colorectal malignancy. Whether an elective or emergent case, significant thought must be given to anastomosis vs stoma creation. Further, these data suggest that higher postoperative attention to infections and sepsis is indicated to prevent worsened morbidity and mortality. Future study is required to determine pathways and therapies by which this risk may be reduced.
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